Exagen Inc (XGN) News

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform

CARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing...

Exagen Inc. to Participate in Fourth Quarter Investor Conferences

CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of...

Exagen Inc. Reports Third Quarter 2024 Results

Expanded AVISE® CTD trailing twelve-month average selling priceReduced Adjusted EBITDA loss for first three...

Exagen to Announce Third Quarter 2024 Results on November 12, 2024

CARLSBAD, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of...

Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence

CARLSBAD, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of...

Form 144 - Report of proposed sale of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference

CARLSBAD, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of...

Form 144 - Report of proposed sale of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Exagen Inc. Reports Strong Second Quarter 2024 Results: Raises Guidance due to Record Performance

CARLSBAD, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of...